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ABSTRACT
Objective We aimed to determine the predictive 
capacity and diagnostic yield of a 10- fold increase in 
serum IgA antitissue transglutaminase (tTG) antibody 
levels for detecting small intestinal injury diagnostic of 
coeliac disease (CD) in adult patients.
Design The study comprised three adult cohorts. Cohort 
1: 740 patients assessed in the specialist CD clinic at 
a UK centre; cohort 2: 532 patients with low suspicion 
for CD referred for upper GI endoscopy at a UK centre; 
cohort 3: 145 patients with raised tTG titres from 
multiple international sites. Marsh 3 histology was used 
as a reference standard against which we determined 
the performance characteristics of an IgA tTG titre of 
≥10×ULN for a diagnosis of CD.
Results Cohort 1: the sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value 
(NPV) for IgA tTG levels of ≥10×ULN at identifying 
individuals with Marsh 3 lesions were 54.0%, 90.0%, 
98.7% and 12.5%, respectively. Cohort 2: the sensitivity, 
specificity, PPV and NPV for IgA tTG levels of ≥10×ULN 
at identifying individuals with Marsh 3 lesions were 
50.0%, 100.0%, 100.0% and 98.3%, respectively. 
Cohort 3: the sensitivity, specificity, PPV and NPV for IgA 
tTG levels of ≥10×ULN at identifying individuals with 
Marsh 3 lesions were 30.0%, 83.0%, 95.2% and 9.5%, 
respectively.
Conclusion Our results show that IgA tTG titres of 
≥10×ULN have a strong predictive value at identifying 
adults with intestinal changes diagnostic of CD. This 
study supports the use of a no- biopsy approach for the 
diagnosis of adult CD.
INTRODUCTION
Coeliac disease (CD) is a common immune- 
mediated enteropathy, whereby increased immu-
nological sensitivity to dietary gluten results in 
chronic small intestinal mucosal inflammation in 
genetically susceptible individuals.1 CD affects 
~1% of the global population, but despite its rising 
prevalence, the majority of patients remain undiag-
nosed.2 Currently, most patients with suspected CD 
Significance of this study
What is already known on this subject?
 ► Paediatric European Society for the Study of 
Paediatric Gastroenterology, Hepatology and 
Nutrition guidelines suggest that a diagnosis 
of coeliac disease (CD) can be made without 
taking duodenal biopsies.
 ► The latest criteria suggest that a 10- fold 
increase in IgA antitissue transglutaminase 
(tTG) antibody levels in combination with EMA 
positivity is sufficient to make a diagnosis of CD 
in the absence of duodenal biopsies.
 ► In adults, this approach has not yet been widely 
adopted into clinical practice, largely due to 
a lack of international multicentre data and 
testing in low CD prevalence cohorts.
What are the new findings?
 ► Across three cohorts of adult patients, we have 
shown that almost all individuals with IgA 
tTG titres of ≥10×ULN have small intestinal 
mucosal changes diagnostic of CD (Marsh 3 
lesions) on duodenal biopsy.
 ► We show that IgA tTG titres of 10×ULN have 
100% specificity at detecting Marsh 3 lesions 
in a cohort of 532 adults with a CD prevalence 
of 3.2%.
 ► Finally, we found that an IgA tTG cut- off 
of 10×ULN performed well at identifying 
individuals with Marsh 3 lesions using different 
assays across multiple international sites. 
However, determining assay- specific thresholds 
and/or standardisation of tTG assays used with 
this pathway may help to optimise the accuracy 
and impact of this approach.
How might it impact on clinical practice in the 
foreseeable future?
 ► This study supports a change in guidelines 
towards a no- biopsy approach for the diagnosis 
of CD within adult gastroenterology services.
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are screened serologically for antibody positivity, in particular 
for IgA antibodies to tissue transglutaminase 2 (tTG) and antien-
domysial IgA antibodies (EMAs).1 As these serological markers 
are not 100% specific for detecting intestinal lesions compat-
ible with CD, positive coeliac serology is confirmed by duodenal 
biopsies demonstrating the hallmark pathological changes of 
mucosal remodelling, such as villous atrophy, crypt hyperplasia 
and intraepithelial lymphocytosis.3
However, upper GI endoscopy with biopsies is expensive, 
with costs relating directly to the procedure and indirectly to the 
processing and analysing of samples. The procedure is poorly 
tolerated by many patients4 and carries risks, including sedation 
complications and although rare in current practice, GI haemor-
rhage and/or perforation.5 Furthermore, variability exists in the 
identification of the main histological changes of CD, meaning 
cases can be missed despite duodenal biopsy sampling.6 7 There-
fore, the identification of a non- invasive approach to the diag-
nosis of CD is of great interest.
The 2012 European Society for the Study of Paediatric Gastroen-
terology, Hepatology and Nutrition (ESPGHAN) guidelines for the 
diagnosis of CD challenged the necessity for duodenal biopsies in 
paediatric patients. They suggested that an IgA tTG antibody titre 
greater than 10 times the upper limit of normal (ULN), in combi-
nation with a positive EMA antibody test and compatible human 
leucocyte antigen (HLA) genotype, is sufficient to support a diag-
nosis of CD in symptomatic individuals.8 This eliminates the need 
for gastroscopy and its associated costs/risks in selected paediatric 
patients.8 The latest guidelines published this year remove the 
requirement for the presence of symptoms and HLA testing in the 
diagnostic pathway.9 This underscores the specificity of a serology- 
based or ‘no- biopsy’ approach for the diagnosis of paediatric CD.
Studies have evaluated whether this strategy can be applied in 
symptomatic adult CD.10–21 These studies have suggested that tTG 
levels of ≥10×ULN could be predictive of CD in adults, and the 
recently published Finnish national guidelines for the diagnosis of 
CD have incorporated this diagnostic pathway into their practice.22 
However, this approach has not been widely adopted into adult clin-
ical practice or guidelines. Adult gastroenterologists have cited the 
lack of international, multicentre data including testing in low CD 
prevalence populations and thus intimated caution.23 Furthermore, 
there are inconsistencies in the histological diagnosis of CD in the 
published literature.23 Therefore, the aim of the current study was 
to assess whether a tTG level of ≥10×ULN could be sufficient for 
detecting duodenal mucosal abnormalities diagnostic of CD and to 
determine the diagnostic yield of this approach across different adult 
cohorts. In doing so, we aimed to address the shortcomings within 
the adult literature.
METHODS
Patients
The study comprised three adult (≥16 years old) cohorts; all 
individuals included in the study underwent clinical assessment 
and had IgA tTG serology testing alongside upper GI endoscopy 
with duodenal biopsies performed.
Cohort 1 comprised a prospective analysis of consecutive 
adult patients assessed in the specialist CD clinic Royal Hallam-
shire Hospital, UK, from 2008 to 2019 who had a serum IgA 
tTG test and duodenal biopsy within 6 weeks of each other, no 
previous diagnosis of CD, naivety to a gluten- free diet (GFD) 
and IgA competency. As these individuals were assessed within 
the specialist coeliac clinic, they were considered as having high 
clinical suspicion for CD.
Cohort 2 comprised a retrospective analysis of a prospec-
tively recruited (December 2014–January 2017)24 cohort of 
adults referred for upper GI endoscopy at the Royal Hallam-
shire Hospital, UK. Patients were recruited prospectively from 
an endoscopy list that is for the investigation of GI complaints, 
as well as general and open- access referrals. Those with IgA defi-
ciency, with a previous diagnosis of CD and on gluten restric-
tion prior to diagnosis were excluded from analysis. To reduce 
the referral bias for CD, patients referred with positive coeliac 
serology (EMA positivity) in primary care were also excluded 
from the analysis. As a result, we considered this cohort as 
having low suspicion for CD.
Cohort 3 comprised a retrospective analysis of adult patients 
with raised tTG titres from multiple sites, involving 8 coun-
tries and comprising 11 laboratories. Cases were identified 
based on positive coeliac serology and having had appropriate 
duodenal biopsy sampling. The eight countries included Argen-
tina (n=11), Iran (n=10), Netherlands (n=10), Italy (n=44), 
Romania (n=10), Turkey (n=10), the USA (n=40) and the UK 
(n=10). In total, this provided assessments on 145 patients.
Serology and biopsy
All patients from cohorts 1 and 2 underwent serological testing 
and duodenal biopsy within 6 weeks of each other at the Royal 
Hallamshire Hospital in the context of a routine clinical service, 
with the exception that histopathologists were blinded to the 
serological status of patients from cohort 2. IgA tTG antibody 
levels were measured by ELISA using the Aeskulisa Diagnos-
tics (Wendelsheim, Germany) kit before December 2014 and 
the ELiA Celikey (Thermo Fisher, Freiburg, Germany) after 
December 2014. Results were reported in unit per millilitre 
using the manufacturer’s supplied reference ranges: 0–15 nega-
tive, >15 positive, 0–7 negative and >7 positive, respectively. 
The highest standard in the assay is 300 and 128 U/mL, respec-
tively, and these were used as upper limits for analysis, irrespec-
tive of whether optical density values exceeded this. IgA EMA 
was detected by immunofluorescence on primate oesophagus 
sections (Binding Site, Birmingham, UK).
During gastroscopy, at least four quadrantic biopsies were 
taken from the second part of the duodenum (D2) and one 
from the duodenal bulb using the single bite technique (21% 
of patients from cohort 1 had >1 D2 biopsy only). The histo-
pathology department at this site had significant experience in 
CD diagnosis. Duodenal mucosal changes were assessed using 
the Marsh criteria; Marsh 3 lesions were classified based on 
evidence of increased intraepithelial lymphocytes, crypt hyper-
plasia and villous atrophy.3 25 The most severe histological grade 
detected on biopsy was recorded and used for analysis. Unless 
otherwise stated, a diagnosis of typical CD was based on posi-
tive coeliac serology and Marsh 3 histology on duodenal biopsy. 
Seronegative CD was diagnosed in individuals with Marsh 3 
lesions and supporting CD risk factors and/or response to a 
GFD; non- coeliac causes of villous atrophy were ruled out in 
these individuals.
Individuals from cohort 3 had IgA tTG titres measured 
by ELISA assays in routine clinical use at each site, including 
ARUP Laboratories (Utah, USA), QuantaLite (Inova Diagnos-
tics, San Diego, California), Eu- tTG (Eurospital, Italy), Euroim-
mune (Luebeck, Germany) and ELiA Celikey (Thermo Fisher, 
Freiburg, Germany). Each individual had four to six duodenal 
biopsies sampled during upper GI endoscopy. A diagnosis of 
CD was made locally by expert gastroenterologists taking into 
consideration serology and duodenal biopsy results.
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Ethical consideration
All identifiable medical information was removed, and all anal-
yses were performed using anonymised data. See below for full 
details.
Statistical analysis
Data handling was conducted using spreadsheets in Microsoft 
Excel (2016); statistical analysis and graph construction were 
performed using GraphPad Prism V.7 (GraphPad Software, San 
Diego, California, USA). To enable comparison of tTG levels 
between different assays, tTG levels were normalised by expres-
sion as a multiple of the ULN—defined as the lowest value that 
was considered abnormal for each assay.19 Where indicated, 
receiver operating characteristic (ROC) curves were constructed, 
and area under the curve (AUC) was calculated to determine the 
accuracy of tTG levels at predicting villous atrophy. Analysis of 
variance or Kruskal- Wallis test, with appropriate post hoc anal-
ysis, was used to compare Marsh grades with tTG titres. A p 
value of <0.05 was considered statistically significant.
RESULTS
Cohort 1: patients assessed in the specialist CD clinic
A total of 740 patients fulfilled the criteria and were included 
in cohort 1. The prevalence of CD in this cohort was 93% 
(690/740 patients). Patient demographics and clinical details are 
listed in figure 1A. Altogether, 380/740 (51%) had tTG titres of 
≥10×ULN. Marsh 3 lesions were detected in 375/380 (98.7%) 
of those with tTG titres of ≥10×ULN (figure 1B). Of the 740 
patients, 360 (49%) had tTG titres of <10×ULN; of those, 
315/360 (87.5%) had Marsh 3 lesions, 35/360 (9.7%) had Marsh 
1–2 lesions and 10/360 (2.8%) had Marsh 0 lesions on duodenal 
biopsy. Based on this, the positive predictive value (PPV) of tTG 
values of ≥10×ULN at predicting mucosal abnormalities with 
villous atrophy was 98.7% (97.0%–99.4%) (figure 1C). Five 
patients had tTG titres of ≥10×ULN without detectable villous 
abnormalities (ie, Marsh<3 lesions); the demographic and clin-
ical characteristics of these patients are shown in table 1. All 
five patients had symptoms of malabsorption and/or were EMA 
positive and all were positive for the HLA DQ2/8 genotype. All 
patients were started on a GFD and subsequently, tTG titres 
decreased.
Two different tTG assays were used to test tTG titres in cohort 
1 over the study period; we next evaluated the differences 
between these two assays. To do this, we divided the cohort into 
two, based on the tTG assay used (cohort 1A, Aeskulisa Diagnos-
tics; cohort 1B, ELiA Celikey). The demographics of individuals 
included in cohort 1A and 1B are detailed in figure 2A. Analysis 
of tTG titres showed that there were differences in the predictive 
power of the two tests, such that applying a 10×ULN cut- off had 
a PPV of 98.1% (95.7%–99.1%) for Marsh 3 lesions in cohort 
Figure 1 (A) Demographic and clinical details of the patients in cohort 1. GI symptoms include abdominal pain, dyspepsia, dysphagia, nausea, 
vomiting, bloating and constipation; extraintestinal symptoms include ataxia, headache, dizziness, fatigue, joint pain and skin rash; malabsorptive 
symptoms include diarrhoea, haematinic deficiencies with/without anaemia and weight loss. (B) Normalised tTG titres against Marsh grade in patients 
from cohort 1. Horizontal bar represents the mean; error bars denote SE of the mean. Black dotted line represents 1×ULN threshold; red dotted line 
represents 10×ULN threshold. Comparisons between groups made with Kruskal- Wallis and post hoc Dunn test. (C) Performance characteristics of tTG 
titres of 10×ULN at predicting villous atrophy. ****P<0.0001. tTG, tissue transglutaminase; ULN, upper limit of normal; PPV, positive predictive value; 
NPV, negative predictive value.
Table 1 Demographic and clinical details of patients with tTG titres≥10×ULN where villous abnormalities were not detected on duodenal biopsies
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 34 42 43 33 46
Gender Female Male Female Male Female
Presenting symptoms Diarrhoea with urgency Diarrhoea, abdominal pain Iron deficiency anaemia, diarrhoea Abdominal pain, bloating, tiredness Iron deficiency anaemia
HLA status DQ2 heterozygous DQ2 homozygous DQ2 heterozygous DQ2 homozygous DQ2 homozygous
EMA test Negative Positive Negative Positive Negative
Family history of CD? No No No No No
TTG at diagnosis 300 300 211 292 182
Marsh grade at diagnosis Marsh 1 Marsh 2 Marsh 2 Marsh 1 Normal
TTG post- GFD 1 8 6 111 1
CD, coeliac disease; EMA, endomysial antibody; GFD, gluten free diet; HLA, human leucocyte antigen; tTG, tissue transglutaminase.
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1A, but a PPV of 100% in cohort 1B (figure 2B–D). Notably, 
the very high tTG titres in patients with Marsh<3 lesions were 
recorded using the Aeskulisa assay (figure 2B).
Cohort 2: patients referred for upper GI endoscopy
A total of 778 patients were included in cohort 2. Ten patients 
had IgA deficiency; 91 patients were already consuming a GFD 
and/or had a diagnosis of CD; 1 patient had clinical features in 
keeping with a relapse of known small bowel Crohn’s disease; 
and 23 individuals had incomplete testing or missing informa-
tion, and so these individuals were excluded from further anal-
ysis. Of the remaining cohort, 121 patients had positive EMA 
testing in primary care, and so these were excluded from further 
analysis.
Therefore, 532 patients were included in the analysis stage. 
The prevalence of CD in this cohort was 3.2% (17/532 patients). 
Patient demographics and clinical details are presented in 
figure 3A. 18/532 patients had Marsh 3 lesions identified on 
duodenal histology, 15 patients (2.8% of the cohort) were diag-
nosed with typical CD; 2 patients (0.4% of the cohort) had sero-
negative CD; and 1 patient (0.2% of the cohort) was diagnosed 
with non- coeliac seronegative villous atrophy.
The ELiA Celikey was used to measure tTG levels in all 
patients in cohort 2. Altogether, 9/532 (1.7%) had tTG titres 
of ≥10×ULN. Marsh 3 lesions were detected in 9/9 (100%) 
of those with tTG titres of ≥10×ULN (figure 3B). All individ-
uals (9/9) with tTG titres of ≥10×ULN were EMA positive. 
Of the 532 patients included, 523 (98.3%) had tTG titres of 
<10×ULN; of those, 9/523 (1.7%) had Marsh 3 lesions; 33/523 
(6.3%) had Marsh 1–2 lesions; and 481/523 (92.0%) had Marsh 
0 lesions on duodenal histology. Thus, the PPV of tTG values of 
≥10×ULN at predicting individuals with Marsh 3 lesions was 
100% (figure 3C).
ROC analysis showed an AUC of 0.9179 for tTG values at 
predicting Marsh 3 histology (figure 4A). Based on this anal-
ysis, the optimal threshold of tTG titres was 5.9×ULN (tTG 
titres of >41.5 U/mL) (figure 4B). Reducing the threshold to 
this level increased the sensitivity of this approach from 50% 
to 61%. These results demonstrate that tTG titres of 10×ULN 
have excellent specificity at detecting Marsh 3 lesions in a cohort 
of predominantly symptomatic adult patients with a low suspi-
cion/prevalence of CD. Reducing the tTG threshold increased 
the number of individuals who would have benefited from this 
strategy, without compromising the predictive value of this 
approach.
Cohort 3: international multicentre cohort
A total of 145 patients were included in cohort 3. The prevalence 
of CD in this cohort was 92% (133/145 patients). Demographic 
and clinical characteristics are included in figure 5A. Of the 145 
patients included, 42 (29.0%) had tTG titres of ≥10×ULN, of 
which 40/42 (95.2%) patients had Marsh 3 lesions on duodenal 
biopsy (figure 5B). One hundred three of the 145 patients 
(71.0%) had tTG titres of <10×ULN; of those, 93/103 (90.3%) 
patients had Marsh 3 lesions; 6/103 (5.8%) patients had Marsh 
1–2 lesions; and 4/103 (3.9%) had Marsh 0 lesions on duodenal 
Figure 2 (A) Demographic and clinical details of the patients in cohorts 1A and 1B. (B) tTG titres against Marsh grade in patients from cohort 1A. 
(C) tTG titres against Marsh grade in patients from cohort 1B. Horizontal bar represents the mean; error bars denote SE of the mean. Black dotted 
line represents 1×ULN threshold; red dotted line represents 10×ULN threshold. Comparisons between groups were made with analysis of variance 
and post hoc Tukey test. (D) Performance characteristics of tTG titres of 10×ULN at predicting villous atrophy. **P<0.01, ****P<0.0001. tTG, tissue 
transglutaminase; ULN, upper limit of normal; PPV, positive predictive value; NPV, negative predictive value.
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biopsy. Based on this, the predictive value of using a 10×ULN 
threshold at detecting individuals with Marsh 3 lesions was 
95.2% (84.6%–98.7%) (figure 5C). Two patients that had 
tTG titres of ≥10×ULN without villous abnormalities both 
had Marsh 2 lesions on duodenal biopsy and were diagnosed 
with CD. Interestingly, tTG titres did not reach the 10×ULN 
threshold across three sites, despite 56 individuals having Marsh 
3 lesions across these sites. Therefore, a uniform tTG threshold 
of 10×ULN may exclude many true positive cases.
DISCUSSION
Altogether this study included 1417 patients; 431/1417 (30%) 
patients had tTG titres of ≥10×ULN, of which 424 (98%) 
patients had Marsh 3 lesions on duodenal biopsy and were diag-
nosed with CD. This study addresses the concerns raised by the 
adult gastroenterology community and supports a change in 
guidelines towards a no- biopsy approach for the diagnosis of 
CD in adults.
We identified Marsh 3 histology as our primary reference 
standard across all cohorts because (1) small intestinal mucosal 
remodelling, in keeping with Marsh 3 histology, represents the 
hallmark pathological changes in CD26; (2) few studies in the 
adult literature have reported on the predictive capacity of tTG 
titres of ≥10×ULN against Marsh 3 histology; rather, a clin-
ical diagnosis of CD (based on the constellation of appropriate 
symptoms, serology and associated risk factors, in the absence 
of villous abnormalities) has been used as a reference standard 
by many27; and (3) few studies have included appropriate details 
regarding the location (including the duodenal bulb) and inter-
pretation of biopsies.28 By contrast, our centre in Sheffield, UK, 
has published extensively on the matter of duodenal biopsy 
sampling in adult CD.29–32
In taking this approach, initially, we evaluated the predictive 
value of tTG titres of ≥10×ULN against the presence of Marsh 
3 histology in patients seen in the specialist CD clinic (cohort 1). 
Most individuals within this cohort were diagnosed with CD, 
which reflects a high referral bias and pretest probability for CD 
in this cohort. This aligns with many previous studies, which 
have also assessed the diagnostic accuracy of tTG titre multi-
ples of the ULN in high pretest probability/disease prevalence 
Figure 3 (A) Demographic and clinical details of the patients in cohort 2. GI symptoms include abdominal pain, dyspepsia, dysphagia, nausea, 
vomiting, bloating and constipation; extraintestinal symptoms include ataxia, headache, dizziness, fatigue, joint pain and skin rash; malabsorptive 
symptoms include diarrhoea, haematinic deficiencies with/without anaemia and weight loss. (B) tTG titres against Marsh grade in patients from 
cohort 2. Horizontal bar represents the mean; error bars denote SE of the mean. Black dotted line represents 1×ULN threshold; red dotted line 
represents 10×ULN threshold. Comparisons between groups were made with analysis of variance and post hoc Tukey test. (C) Performance 
characteristics of tTG titres of 10×ULN at predicting villous atrophy. ****P<0.0001. tTG, tissue transglutaminase; ULN, upper limit of normal; PPV, 
positive predictive value; NPV, negative predictive value.
Figure 4 (A) Receiver operating characteristic curve analysis of tTG values against Marsh 3 histology in cohort 2. (B) Performance characteristics 
of tTG titres×5.9 ULN at predicting Marsh 3 lesions. tTG, tissue transglutaminase; ULN, upper limit of normal; PPV, positive predictive value; NPV, 
negative predictive value.
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populations (CD prevalence >70%).10 12–14 16 18 In accordance 
with these previous studies, we found that a tTG titre threshold 
of 10×ULN accurately identified individuals with Marsh 3 
lesions.
However, the pretest probability/disease prevalence within a 
cohort can influence the PPV of a diagnostic test.33 This means 
that as the disease prevalence increases, the more likely it is that 
a positive test represents a true positive case.33 The predictive 
value of the 10×ULN threshold in adults has less commonly 
been evaluated in more general clinical scenarios where the 
disease prevalence of CD is considered <10%.11 28 33 Sugai et 
al previously demonstrated that a tTG titre threshold of around 
7×ULN had a 100% PPV for CD in an adult cohort with a CD 
prevalence of 3.3%.11 More recently, Fuchs et al demonstrated 
that a tTG titre threshold of 10×ULN was accurate at identi-
fying individuals with Marsh 3 lesions across adult cohorts with 
different pretest probabilities for CD.28 However, in this study, 
the low CD pretest probability cohort included only older (>50 
years) adults.28 Furthermore, the performance characteristics of 
the 10×ULN tTG threshold in a more general clinical scenario 
have been estimated, but not studied.33
Therefore, to confirm and extend these findings, we next 
sought to determine the predictive capacity of the 10×ULN 
threshold against the presence of Marsh 3 lesions on duodenal 
biopsy in a cohort of individuals considered as low suspicion 
for CD (cohort 2). Low suspicion was determined on the basis 
that, in those referred for upper GI endoscopy, the referral bias 
for CD was removed by excluding those who tested positive 
for CD in primary care. Indeed, the prevalence of CD in this 
population was 3.2%, which aligns with the local prevalence 
of CD in symptomatic adults in primary care (3.6%).34 These 
results demonstrate that tTG titres of ≥10×ULN are equally 
good at predicting Marsh 3 lesions in the setting of both low 
and high disease pretest probability/prevalence and comple-
ment previous work that this diagnostic pathway can be used in 
adults with different risk levels for CD.11 28 Importantly, while 
these data support the use of the biopsy avoidance approach 
in adults, we still advocate that suspected cases with tTG titres 
exceeding the 10× threshold are referred to a gastroenterologist 
for assessment, rather than the diagnosis of CD being made in 
primary care. In addition, these data were generated in adult 
cohorts within secondary and tertiary care settings, and thus, 
these results do not apply to screening the general population 
for a diagnosis of CD. These are important considerations to 
ensure that patients receive the correct diagnosis and to prevent 
the inappropriate institution of a GFD, which has been raised as 
concerns regarding this approach by some.23 35
One of the major challenges in implementing this diagnostic 
pathway is the variability and lack of standardisation between 
tTG assays.36 The inability to compare tTG results accurately 
between different assays increases the chances of misdiagnosis if 
a uniform threshold is used. In adults, there is a lack of data eval-
uating this in a multicentre international setting. To address this, 
we evaluated the 10×ULN threshold across multiple sites/coun-
tries and multiple assays (cohort 3). The PPV of the 10×ULN 
threshold at detecting Marsh 3 lesions dropped from nearly 99% 
across cohorts 1 and 2 at our UK centre to 95.2% in a multi-
centre international setting. This raises the concern that sole 
reliance on this as a marker for CD will lead to a false- positive 
diagnosis in around 1 in 20 cases.
Across all cohorts, the diagnostic performance of this pathway 
is based strictly on the presence of Marsh 3 histology. The PPV 
in all three cohorts increased to >99%, where both Marsh 2 and 
Marsh 3 lesions are accepted as CD. It is widely accepted that in 
the setting of relevant symptoms/high baseline risk of CD, raised 
serological markers, HLA DQ2/8 positivity and/or response to a 
GFD, the diagnosis of CD can be established in the absence of 
villous effacement. Indeed, this situation may represent a false- 
negative histology rather than a false- positive serology28 due to 
a variety of reasons, including incorrect histological interpreta-
tion, which can vary in 10%–25% of cases between independent 
evaluations6 7 and/or patchy disease.32 Additionally, individuals 
with symptomatic CD may present with subtle villous abnor-
malities that fall within the scope of microscopic enteritis, which 
may lead to diagnostic inaccuracy.37
In comparison with the datasets that have evaluated the 
tTG IgA cut- off at ≥10×ULN included in the latest paediatric 
ESPGHAN guidelines, 2/30 reported a PPV of <95%; 7/30 had 
a PPV between 95% and 99%; and 21/30 reported a PPV of 
>99% for detecting Marsh 3 lesions.9 In studies where Marsh 
Figure 5 (A) Demographic and clinical details of the patients in cohort 3. GI symptoms include abdominal pain, dyspepsia, dysphagia, nausea, 
vomiting, bloating and constipation; extraintestinal symptoms include ataxia, headache, dizziness, fatigue, joint pain and skin rash; malabsorptive 
symptoms include diarrhoea, haematinic deficiencies with/without anaemia and weight loss. (B) Normalised tTG titres against Marsh grade in patients 
from cohort 3. Horizontal bar represents the mean; error bars denote SE of the mean. Black dotted line represents 1×ULN threshold; red dotted line 
represents 10×ULN threshold. Comparisons between groups made with Kruskal- Wallis and post hoc Dunn test. (C) Performance characteristics of tTG 
titres of 10×ULN at predicting villous atrophy. **P<0.01. tTG, tissue transglutaminase; ULN, upper limit of normal; PPV, positive predictive value; NPV, 
negative predictive value.
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2 or Marsh 3 duodenal lesions were accepted for a diagnosis 
of CD, the PPV was >97% in all studies.9 Thus, based on the 
current study, the performance characteristics of this diagnostic 
pathway in adults with different risk levels for CD or in a multi-
centre international setting is at least comparable with the studies 
included within the paediatric guidelines.
The high tTG threshold recommended by the paediatric 
community in part is included to control for tTG assay varia-
tion.36 We found that for some tTG assays, a lower cut- off may 
retain diagnostic specificity but increase the sensitivity of this 
approach. In contrast, the 10×ULN threshold may not eliminate 
all false- positive cases across all assays. Therefore, a uniform 
threshold may hinder the clinical impact and accuracy of the 
no- biopsy approach in adult patients. Other studies have reported 
similar findings of differences in the optimal tTG thresholds and 
performance characteristics of different assays.14 19 28 This does 
not imply that one assay is inferior to the other nor that using 
tTG threshold values in this manner is not appropriate, rather 
that the threshold ULN cut- off should be specific to the tTG 
assay, as there is currently no way to accurately standardise tTG 
results across different assays.38 Therefore, local validation of 
assay specific thresholds and/or limiting the use of this pathway 
to certain tTG assays may help to optimise the clinical impact 
and accuracy of this approach.
The latest ESPGHAN guidelines no longer consider either the 
presence of symptoms or HLA typing as mandatory in this diag-
nostic pathway.9 HLA typing has been shown to add no diag-
nostic value in this pathway in children or adults, and testing is 
costly and not widely available.9 28 Therefore, the HLA status of 
individuals was not specifically evaluated in this study. In addi-
tion, while each cohort comprised predominantly symptomatic 
adults, we did not specifically evaluate symptomatology in this 
study. Current ESPGHAN guidelines recommend confirming 
tTG titres with EMA positivity in a second blood sample.9 EMA 
status was not evaluated in all patients in the present study. 
While EMA positivity has been shown to enhance the predictive 
capacity of the biopsy avoidance approach, EMA testing incurs a 
high cost and is labour intensive, and the interpretation is subjec-
tive.35 For these reasons, some centres have stopped performing 
EMA tests.17 Therefore, including EMA testing in this algo-
rithm may lead to poor uptake of this pathway in some areas. 
Alternative strategies have been suggested, including simulta-
neous tTG measurements28 or testing for deamidated gliadin 
peptides (DGPs) alongside tTG titres, the latter of which has 
shown promise in both adult and paediatric cohorts.11 39 Further 
adult studies are awaited to address the place for DGPs in this 
algorithm.
Finally, it is noteworthy that the applicability of the biopsy 
avoidance approach is not as straightforward in adults as it is 
in children. Indeed, it should be stressed there are a number 
of reasons that a biopsy should still be performed in adults, 
particularly if there are ‘red flag’ signs/symptoms, such as, but 
not limited to, persistent dyspepsia in those aged ≥55 years, 
weight loss, severe malnutrition, dysphagia and unexplained 
iron deficiency anaemia.40–42 Some of these presentations align 
with those of adult CD; this underscores the importance of 
assessment by a gastroenterologist before a diagnosis of CD is 
made in the absence of a duodenal biopsy. In addition, a biopsy 
should also be considered in cases of discordance between 
serology and risk, and in borderline cases.27 Moreover, indi-
viduals with persistent symptoms despite adherence to a GFD 
require duodenal biopsy sampling, as tTG titres provide no 
information regarding histological improvement after intro-
duction of a GFD.43
In conclusion, our data show that anti- tTG titres of ≥10×ULN 
perform well at identifying adults with intestinal changes asso-
ciated with CD. This study supports a no- biopsy strategy in 
adult gastroenterology services. This approach has implications 
in reducing the cost, risk and caseload associated with diag-
nostic endoscopy in adult CD. However, local validation of 
assay- specific thresholds would enable this approach to have the 
greatest impact on adult patients.
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